Latest news with #Tepezza
Yahoo
28-07-2025
- Business
- Yahoo
2 Top Dividend Stocks to Buy Right Now and Hold Forever
Key Points Amgen can replenish its lineup thanks to a deep pipeline. AbbVie has a knack for getting around headwinds. Both drugmakers have strong dividend track records. 10 stocks we like better than Amgen › Over the long run, dividends can make a significant difference in your returns, whether you choose to reinvest the payouts or retain the cash for other purposes. However, many companies that offer dividends aren't exactly attractive to hold on to for a long time. Some have somewhat shaky underlying operations, and others are not inclined to regularly raise their dividends. Thankfully, some income stocks on the market don't have these issues, and their shares are worth holding on to forever. Let's consider two examples: Amgen (NASDAQ: AMGN) and AbbVie (NYSE: ABBV). 1. Amgen If you're an income-seeking investor, Amgen has several qualities that you'll appreciate. First, it's a leader in healthcare, a defensive industry. The demand for the medicines that the company develops -- some of which are lifesaving -- won't stop even during economic downturns, nor will physicians stop prescribing them. Amgen is well equipped to perform regardless of economic conditions. The drugmaker generates consistent revenue and earnings. Second, it continues to innovate. True, it has encountered clinical setbacks of late; its investigational weight management medicine, MariTide, didn't perform as well in mid-stage studies as expected. However, the company recently reported phase 3 results for bemarituzumab, a medicine it's developing for gastric cancer, the fifth leading cause of cancer death worldwide. This product now appears likely to secure regulatory approval and make a meaningful contribution to Amgen's results for a while. The company will continue to face competition and patent cliffs, but it's been able to perform well over the long run despite these challenges, thanks to its innovative abilities. Amgen can also rely on licensing deals and acquisitions to bolster its lineup and pipeline. In 2023, it acquired Horizon Therapeutics and its medicine for thyroid eye disease, Tepezza, for about $28 billion. Amgen has been able to push Tepezza's reach far beyond what the smaller Horizon would have been able to accomplish; it earned approval for the medicines in countries like Japan and Brazil, while pouring money into advertising and marketing efforts. Third, Amgen has a strong track record of dividend payments. The biotech initiated a payout in 2011, and since then, it's increased its dividends every single year. It currently offers a forward yield of 3.1%, considerably higher than the S&P 500's average of 1.3%. And the cash payout ratio of 46.5% appears reasonable, leaving ample room for further payout increases. Amgen's ability to develop novel lifesaving medicines, its consistent financial results, and its regular payout increases make it a top dividend stock to buy and hold for the long term. 2. AbbVie Although AbbVie has lagged behind the market over the past three years, this period highlights the company's resilient qualities. After losing patent exclusivity in January 2023 for Humira, an immunology medicine that was its best-selling drug and also the most lucrative in the industry's history, management predicted that the company would return to top-line growth in 2025. AbbVie resumed revenue growth last year, ahead of schedule. It's not rare for drugmakers to go through several years of declining revenue following a major patent cliff, nor is it necessarily a cause for concern. AbbVie's ability to bounce back as quickly as it did speaks volumes about the strength of its underlying business, its ability to navigate competition -- biosimilar and otherwise -- and its long-term prospects. True, the company encountered a significant setback when a seemingly promising candidate for schizophrenia called emraclidine, which it had gotten its hands on through an acquisition, failed mid-stage studies. AbbVie has faced similar problems before and has bounced back. The company had bet on a cancer medicine called Rova-T to be a significant growth driver post-Keytruda. However, this medicine failed in the clinic. Instead, AbbVie is now relying on Skyrizi and Rinvoq, two immunosuppressants, to drive top-line growth. These medicines have surpassed its own expectations, and they should continue to be significant contributors for years to come. The company has consistently found ways to overcome setbacks and challenges. Its financial results remain robust; the pipeline is deep; the balance sheet is strong. And its dividend track record is outstanding: AbbVie is a Dividend King, boasting 53 consecutive years of payout increases. Its forward yield now tops 3.4%, while the cash payout ratio of 61.8% is still reasonable. This is another dividend stock that you could safely include in a long-term portfolio. Should you invest $1,000 in Amgen right now? Before you buy stock in Amgen, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Amgen wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* Now, it's worth noting Stock Advisor's total average return is 1,041% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 28, 2025 Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AbbVie and Amgen. The Motley Fool has a disclosure policy. 2 Top Dividend Stocks to Buy Right Now and Hold Forever was originally published by The Motley Fool
Yahoo
20-07-2025
- Business
- Yahoo
Why Amgen (AMGN) Could Be a Hidden Gem Among Dividend Pharma Stocks in 2025
Amgen Inc. (NASDAQ:AMGN) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. A pharmacist filling a prescription for a complex drug developed by the company. In 2023, the company finalized its $28 billion acquisition of Horizon Therapeutics, a smaller biotech firm. This move helped broaden Amgen's product portfolio and reduced its reliance on older drugs like Enbrel, which are expected to weigh on future revenue and profit growth. The acquisition also brought in new growth opportunities, especially with Tepezza, the first FDA-approved treatment for thyroid eye disease. In the first quarter of 2025, Amgen Inc. (NASDAQ:AMGN) reported revenue of $8.15 billion, which showed a 9.4% growth from the same period last year. The company reported strong global demand for its products in the first quarter. Management expressed confidence in its long-term growth outlook, citing continued success with new product launches and positive Phase 3 trial results for several treatments. Amgen Inc. (NASDAQ:AMGN)'s free cash flow for the quarter came in at $1.0 billion, up from $0.5 billion in the prior year period. Its operating cash flow was $1.4 billion, compared to $0.7 billion in the same period last year. The company also returned $1.3 billion to shareholders through dividends during the quarter. Currently, it offers a quarterly dividend of $2.38 per share and has a dividend yield of 3.19%, as of July 17. The company has raised its payouts since the inception of its dividend policy in 2011. While we acknowledge the potential of AMGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Sign in to access your portfolio
Yahoo
19-07-2025
- Business
- Yahoo
Why Amgen (AMGN) Could Be a Hidden Gem Among Dividend Pharma Stocks in 2025
Amgen Inc. (NASDAQ:AMGN) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. A pharmacist filling a prescription for a complex drug developed by the company. In 2023, the company finalized its $28 billion acquisition of Horizon Therapeutics, a smaller biotech firm. This move helped broaden Amgen's product portfolio and reduced its reliance on older drugs like Enbrel, which are expected to weigh on future revenue and profit growth. The acquisition also brought in new growth opportunities, especially with Tepezza, the first FDA-approved treatment for thyroid eye disease. In the first quarter of 2025, Amgen Inc. (NASDAQ:AMGN) reported revenue of $8.15 billion, which showed a 9.4% growth from the same period last year. The company reported strong global demand for its products in the first quarter. Management expressed confidence in its long-term growth outlook, citing continued success with new product launches and positive Phase 3 trial results for several treatments. Amgen Inc. (NASDAQ:AMGN)'s free cash flow for the quarter came in at $1.0 billion, up from $0.5 billion in the prior year period. Its operating cash flow was $1.4 billion, compared to $0.7 billion in the same period last year. The company also returned $1.3 billion to shareholders through dividends during the quarter. Currently, it offers a quarterly dividend of $2.38 per share and has a dividend yield of 3.19%, as of July 17. The company has raised its payouts since the inception of its dividend policy in 2011. While we acknowledge the potential of AMGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None.
Yahoo
06-06-2025
- Business
- Yahoo
2 Dividend Growth Stocks to Buy and Hold Forever
Despite recent headwinds, these drugmakers have strong underlying businesses. Their pipelines should enable them to navigate patent cliffs and support top-line growth. Novartis and Amgen also boast impeccable dividend track records, which should please investors. 10 stocks we like better than Amgen › When broader equities are volatile, it's tempting to focus on what's going to happen in the near term. That's why some investors resort to panic selling -- they anticipate that things will get even worse than they already are. However, one of the formulas for better-than-average long-term returns is to stick with your holding even when the going gets rough, unless there is some fundamental change to a company's investment thesis. In fact, even when the near-term is somewhat uncertain, it's still worth it to invest in corporations that can perform well over many decades. Let's consider two examples in the healthcare sector: Amgen (NASDAQ: AMGN) and Novartis (NYSE: NVS). These drugmakers have a lot to offer long-term, income-oriented investors. Amgen's organic revenue hasn't always grown as fast as Wall Street would have wanted over the past few years. One of the company's promising candidates to change that, investigational weight management product MariTide, did not post phase 2 data on par with what analysts and investors wanted either. Despite these short-term challenges, the company's prospects remain attractive. Clinical setbacks are par for the course for biotech companies, that is, if MariTide results even count as a setback. The medicine produced a mean weight loss of approximately 20% after 52 weeks, with no plateau observed, and all this with convenient once-monthly dosing; the current leading anti-obesity medicines are administered weekly. Even with lower efficacy, MariTide could go on to attract a reasonable number of patients thanks to its friendlier dosing schedule. In addition to this investigational medicine, Amgen boasts a comprehensive lineup of products across several therapeutic areas, including several that generate over $1 billion in annual sales. Despite top-line growth that doesn't always meet or exceed expectations, Amgen generates consistent revenue and profits. The biotech leader also has several medicines in its arsenal that should help it drive decent growth for a while. Asthma treatment Tezspire has been making strides on the market and in the clinic. Tepezza remains the only medicine for thyroid eye disease approved by the U.S. Food and Drug Administration. There are several other key products in Amgen's portfolio. More importantly, the company has a pipeline with dozens of investigational drugs that will allow it to overcome competition and patent cliffs over the long run. Lastly, Amgen has a great dividend track record. It has raised its payouts every year since first initiating them in 2011. In the past decade, Amgen's dividend has increased by 201.3%. It offers a forward yield of 3.3%, well above the S&P 500's average of 1.3%. It is well worth it for income seekers to buy this stock and hold it for good. Novartis, another leading drugmaker, is facing a significant patent cliff this year. The company's heart failure medication, Entresto, is running out of exclusivity in the U.S. That's a big problem since Entresto was Novartis' top-selling medicine last year, generating $7.8 billion in revenue in 2024. Novartis will likely see its revenue decrease for a while, as pharmaceutical giants tend to do when encountering major patent cliffs. However, Novartis should eventually overcome this obstacle. Several newer medicines will help smooth out Entresto-related losses. For instance, Pluvicto, a cancer medicine first approved in the U.S. in 2022, is making steady progress. It is already generating over $1 billion in annual sales and is still going strong. It should keep driving sales growth into the next decade. Leqvio, a therapy to help reduce cholesterol that first hit the U.S. market in 2021, should also help. Some of Novartis' older drugs will maintain an upward sales trajectory for a while, too. The Swiss drugmaker also has a deep pipeline, boasting a little over 100 programs across multiple therapeutic areas. Expect regular brand-new approvals and label expansions for the drugmaker. Lastly, Novartis has an impressive dividend track record. The company's forward yield tops 3.5%, and, importantly, it has increased its dividends for 28 consecutive years. Novartis may not be attractive to growth-oriented investors, particularly as it navigates the Entresto patent cliff. However, the company has a robust business that generates consistent results, a deep pipeline to help mitigate patent-related challenges, and a history of rewarding shareholders with dividend hikes. Investors can safely add this stock to their "forever" dividend portfolio. Before you buy stock in Amgen, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Amgen wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,538!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $869,841!* Now, it's worth noting Stock Advisor's total average return is 789% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amgen. The Motley Fool has a disclosure policy. 2 Dividend Growth Stocks to Buy and Hold Forever was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
17-04-2025
- Business
- Yahoo
2 Dividend Stocks Defying the Tariff-Fueled Market Correction to Buy and Hold Forever
Equities are down this year because of Donald Trump's trade policies. The 47th U.S. president decided to impose steep tariffs on imported goods from most countries, although he has since significantly rolled back -- or at least paused -- these plans. Amid all the volatility, some companies are proving resilient by performing much better than the market. Some of these look like excellent buy-and-hold options, especially for income-seeking investors. Let's consider two such corporations: Amgen (NASDAQ: AMGN) and Novartis (NYSE: NVS). Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » Although President Trump has spared the pharmaceutical industry from tariffs for now, his administration has indicated that could change soon. That means drugmakers like Amgen might see a meaningful effect on their bottom line. According to some CEOs in the industry, tariffs could even lead to less innovation in the field. Still, developing lifesaving drugs is a business that will never be out of style, regardless of economic conditions. Drugmakers that can adapt will likely perform well in the long run. Amgen is one of them. The biotech has a long list of approved medicines across multiple therapeutic areas. Last year, it had 13 products that generated at least $1 billion in annual sales. Most of these saw their sales move in the right direction. Amgen boasts several exciting growth drivers. Tepezza remains the only therapy approved by the U.S. Food and Drug Administration (FDA) for thyroid eye biotech is aiming for regulatory approvals for this medicine in other countries, which will help boost its sales. Amgen's therapy for asthma, Tezspire, co-marketed with AstraZeneca, is also performing well and continues to record important clinical wins that will lead to label expansions. Older drugs such as Repatha for high cholesterol and Evenity, used to treat the bone disease osteoporosis in post-menopausal women, are still among Amgen's best performers. Lastly, the company has a deep pipeline. Despite phase 2 data for its weight management candidate, MariTide, that failed to impress, this investigational medicine could still go on to carve out a solid niche in the fast-growing weight loss market. Amgen has plenty of other exciting programs in the pipeline. Amid all the economic issues we have experienced in the past five years, the biotech has continued to increase its dividends. Amgen's payouts have grown by 201% in the past decade, and it offers a forward yield of 3.2% at Wednesday's prices. Amgen's strong presence in a defensive industry, excellent innovative track record, and strong dividend program make it a top stock to hold on to for good. Novartis is already planning to get around any tariffs imposed on the pharmaceutical industry. The drugmaker recently announced a five-year, $23 billion manufacturing project in the U.S. This move could help in the long run, but it especially highlights an important point about massively successful corporations: They have the financial flexibility to adapt to changing economic conditions. Novartis owes that to its solid underlying operations. Its top-line growth rarely blows investors away, but it records steady revenue and profits. In today's volatile environment, slow and steady might be what the doctor ordered. True, Novartis will face some patent cliffs this year, none more critical than Entresto, a heart failure medicine that is the company's top-selling drug. Novartis' revenue might drop once that happens, as it typically does for any drugmaker that loses patent exclusivity for its best-selling product. However, Novartis should be able to move past it. The company has several newer growth drivers that will gain prominence. Fabhalta, a therapy for a rare blood disease, earned the green light in 2023, while Vanrafia, a medicine for a kidney disease, did so just this month. Novartis' deep pipeline will lead to more approvals down the line. The company's dividend track record speaks volumes about its ability to navigate challenging conditions. Novartis has increased its payouts for 28 consecutive years. The company also offers a dividend yield of 3.5%. Whether it's for stability or income, Novartis is a great forever pick for investors. Before you buy stock in Amgen, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Amgen wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $518,599!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $640,429!* Now, it's worth noting Stock Advisor's total average return is 794% — a market-crushing outperformance compared to 153% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of April 14, 2025 Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amgen. The Motley Fool recommends AstraZeneca Plc. The Motley Fool has a disclosure policy. 2 Dividend Stocks Defying the Tariff-Fueled Market Correction to Buy and Hold Forever was originally published by The Motley Fool Sign in to access your portfolio
